Skip to content

Oxford Biomedica PLC Sustainability Reports

Oxford Biomedica plc operates as a pure-play contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company provides process development and manufacturing services for viral vectors including lentivirus, adeno-associated virus, and adenoviral vectors.

Sector: Professional & technical services

Country: United Kingdom

Exchange: London Stock Exchange

ISIN: GB00BDFBVT43

15 reports from 2011 to 2025